Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone908-947-3120
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.86 billion
Profitability
Miscellaneous
Employees6,000
Next Earnings Date2/26/2020 (Confirmed)
OptionableOptionable
Amneal Pharmaceuticals (NYSE:AMRX) Frequently Asked Questions
What is Amneal Pharmaceuticals' stock symbol?
Amneal Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "AMRX."
How were Amneal Pharmaceuticals' earnings last quarter?
Amneal Pharmaceuticals Inc (NYSE:AMRX) released its earnings results on Wednesday, November, 6th. The company reported $0.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.13 by $0.09. The firm earned $378.30 million during the quarter, compared to analyst estimates of $403.90 million. Amneal Pharmaceuticals had a negative net margin of 19.61% and a positive return on equity of 23.17%. Amneal Pharmaceuticals's quarterly revenue was down 20.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.28 EPS. View Amneal Pharmaceuticals' Earnings History.
When is Amneal Pharmaceuticals' next earnings date?
How can I listen to Amneal Pharmaceuticals' earnings call?
Amneal Pharmaceuticals will be holding an earnings conference call on Wednesday, February 26th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What price target have analysts set for AMRX?
12 brokerages have issued twelve-month price objectives for Amneal Pharmaceuticals' shares. Their forecasts range from $2.50 to $14.00. On average, they anticipate Amneal Pharmaceuticals' stock price to reach $6.30 in the next twelve months. This suggests a possible upside of 44.9% from the stock's current price. View Analyst Price Targets for Amneal Pharmaceuticals.
What is the consensus analysts' recommendation for Amneal Pharmaceuticals?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last year. There are currently 2 sell ratings, 6 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Amneal Pharmaceuticals.
What are Wall Street analysts saying about Amneal Pharmaceuticals stock?
Here are some recent quotes from research analysts about Amneal Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Amneal Pharmaceuticals LLC is an integrated specialty pharmaceutical company. It focused on developing, manufacturing and distributing generic, brand and biosimilar products. The company operates primarily in North America, Asia and Europe. Amneal Pharmaceuticals LLC, formerly known as Impax Laboratories Inc., is based in New Jersey, United States. " (2/11/2020)
- 2. Cantor Fitzgerald analysts commented, ". We reiterate our OW rating and 12-month PT of $35 for AMRX shares post a 4Q18 beat and despite lower than anticipated guidance for 2019. We still believe that AMRX will be able to successfully grow from a mid-size generics company into a leading generics and specialty pharma company. Therefore, upward earnings revisions in 2020+ should drive the stock higher. These upward earnings revisions should come from: 1) new generic drug launches, 2) operating margin expansion, 3) high-margin brand drug sales, and 4) strategic M&A as well as tuck-in deals." (2/28/2019)
Has Amneal Pharmaceuticals been receiving favorable news coverage?
News headlines about AMRX stock have been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Amneal Pharmaceuticals earned a news sentiment score of 1.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Amneal Pharmaceuticals.
Are investors shorting Amneal Pharmaceuticals?
Amneal Pharmaceuticals saw a increase in short interest in January. As of January 31st, there was short interest totalling 5,420,000 shares, an increase of 9.3% from the January 15th total of 4,960,000 shares. Based on an average trading volume of 2,960,000 shares, the short-interest ratio is currently 1.8 days. Approximately 6.6% of the company's stock are short sold. View Amneal Pharmaceuticals' Current Options Chain.
Who are some of Amneal Pharmaceuticals' key competitors?
Some companies that are related to Amneal Pharmaceuticals include United Therapeutics (UTHR), Global Blood Therapeutics (GBT), BridgeBio Pharma (BBIO), Nektar Therapeutics (NKTR), Evotec (EVTCY), FibroGen (FGEN), Arrowhead Pharmaceuticals (ARWR), GW Pharmaceuticals PLC- (GWPH), Mirati Therapeutics (MRTX), Blueprint Medicines (BPMC), Agios Pharmaceuticals (AGIO), SAGE Therapeutics (SAGE), Zai Lab (ZLAB), PTC Therapeutics (PTCT) and Emergent Biosolutions (EBS).
What other stocks do shareholders of Amneal Pharmaceuticals own?
Who are Amneal Pharmaceuticals' key executives?
Amneal Pharmaceuticals' management team includes the folowing people:
- Mr. Paul M. Bisaro, Exec. Chairman (Age 58)
- Mr. Chirag K. Patel, Co-Founder & Co-Chairman (Age 52)
- Mr. Chintu Patel, Co-Founder & Co-Chairman (Age 47)
- Mr. Robert A. Stewart, Pres, CEO & Director (Age 51)
- Ms. Nikita Shah, Sr. VP & Chief HR Officer (Age 41)
Who are Amneal Pharmaceuticals' major shareholders?
Amneal Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include State Street Corp (0.76%), Geode Capital Management LLC (0.51%), Bank of New York Mellon Corp (0.44%), Prudential Financial Inc. (0.31%), Mackay Shields LLC (0.26%) and Bank of America Corp DE (0.24%). Company insiders that own Amneal Pharmaceuticals stock include Andrew S Boyer, Bryan M Reasons, International Ltd Fosun, Joseph Todisco, Nikita Shah, Paul Bisaro, Peter R Terreri, Pradeep Bhadauria and Ted C Nark. View Institutional Ownership Trends for Amneal Pharmaceuticals.
Which major investors are selling Amneal Pharmaceuticals stock?
AMRX stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Spark Investment Management LLC, Strs Ohio, First Trust Advisors LP, Cubist Systematic Strategies LLC, Goldman Sachs Group Inc., UBS Asset Management Americas Inc. and Meeder Asset Management Inc.. View Insider Buying and Selling for Amneal Pharmaceuticals.
Which major investors are buying Amneal Pharmaceuticals stock?
AMRX stock was bought by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Mackay Shields LLC, Marshall Wace LLP, Bank of America Corp DE, State Street Corp, Geode Capital Management LLC, Panagora Asset Management Inc. and Alambic Investment Management L.P.. Company insiders that have bought Amneal Pharmaceuticals stock in the last two years include Andrew S Boyer, International Ltd Fosun, Joseph Todisco, Paul Bisaro, Pradeep Bhadauria and Ted C Nark. View Insider Buying and Selling for Amneal Pharmaceuticals.
How do I buy shares of Amneal Pharmaceuticals?
Shares of AMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Amneal Pharmaceuticals' stock price today?
One share of AMRX stock can currently be purchased for approximately $4.35.
How big of a company is Amneal Pharmaceuticals?
Amneal Pharmaceuticals has a market capitalization of $1.30 billion and generates $1.86 billion in revenue each year. The company earns $-169,730,000.00 in net income (profit) each year or $0.95 on an earnings per share basis. Amneal Pharmaceuticals employs 6,000 workers across the globe.View Additional Information About Amneal Pharmaceuticals.
What is Amneal Pharmaceuticals' official website?
How can I contact Amneal Pharmaceuticals?
Amneal Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The company can be reached via phone at 908-947-3120 or via email at [email protected]
MarketBeat Community Rating for Amneal Pharmaceuticals (NYSE AMRX)
MarketBeat's community ratings are surveys of what our community members think about Amneal Pharmaceuticals and other stocks. Vote "Outperform" if you believe AMRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
